Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
The Retrofit: Lessons From Sotorasib's Dosing Conundrum
Harpreet Singh, Paz J Vellanki, Richard Pazdur
JCO Precision Oncology
|
September 27, 2021
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by <i>FANCM</i> Mutations
Paz J Vellanki, Emily A DeBoy, M Malek Bawadkji, et al.
Journal for Immunotherapy of Cancer
|
February 16, 2023
Regulatory implications of ctDNA in immuno-oncology for solid tumors
Paz J Vellanki, Soma Ghosh, Anand Pathak, et al.
Cancer Cell
|
April 10, 2023
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers
Kristen E Schratz, Diane A Flasch, Christine C Atik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
Erica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review
Paz J Vellanki, Flora Mulkey, Adnan A Jaigirdar, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review
Abigail L Koch, Paz J Vellanki, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
The Retrofit: Lessons From Sotorasib's Dosing Conundrum
Harpreet Singh, Paz J Vellanki, Richard Pazdur
JCO Precision Oncology
|
September 27, 2021
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by <i>FANCM</i> Mutations
Paz J Vellanki, Emily A DeBoy, M Malek Bawadkji, et al.
Journal for Immunotherapy of Cancer
|
February 16, 2023
Regulatory implications of ctDNA in immuno-oncology for solid tumors
Paz J Vellanki, Soma Ghosh, Anand Pathak, et al.
Cancer Cell
|
April 10, 2023
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers
Kristen E Schratz, Diane A Flasch, Christine C Atik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
Erica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review
Paz J Vellanki, Flora Mulkey, Adnan A Jaigirdar, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review
Abigail L Koch, Paz J Vellanki, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Page
of 1